Certain weight-loss drugs linked to lower dementia risk
At 10 years, users without diabetes had lower dementia risk than multivitamin users (relative risk 0.17) and phentermine users (0.64).
Our read
Populations- Studied:
- Cohort study of 57,066 adults aged 55 or older without diabetes, 10 years, against multivitamin users
- What changed:
- Dementia risk was lower with GLP-1RA use than multivitamin use at 10 years (RR 0.17, 95% CI 0.15-0.19)
- The catch:
- Differences in health or care between groups could have influenced dementia diagnoses
- Why it’s aging research:
- It studies an intervention with evidence of extending healthy life.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults aged 55 or older without diabetes and with a body mass index—a weight-for-height measure—of at least 27 were included in an observational study of obesity treatment. Researchers emulated two trials comparing glucagon-like peptide-1 receptor agonists, drugs used for weight loss, with multivitamins or phentermine, another weight-loss drug. Matched cohorts numbered 57,066 for the multivitamin comparison and 26,155 for phentermine.
The researchers matched groups on characteristics including age, sex, cardiovascular conditions and medications. Drug use was associated with lower risks of dementia, frailty and mild cognitive impairment—milder problems with memory or thinking—at five and 10 years. Associations were weaker against phentermine than against multivitamins. A relative risk below 1 indicates lower risk than in the comparison group.
Why it matters
Dementia is a major concern in later life. The authors suggested that these drugs may offer brain-protective benefits beyond weight reduction alone.
Caveats
Matching could not rule out differences in health or care between drug users and comparison groups that influenced dementia diagnoses. These conference-abstract findings covered adults aged 55 or older without diabetes, not younger adults or people with diabetes.
The paper
Glucagon-Like Peptide-1 Receptor Agonist Use and Neurocognitive Outcomes in Adults Without Diabetes
Section of Cardiovascular Medicine; Yale Sch of Medicine
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 10552
Comments
Be the first to comment.